SYNCOM FORMULATIONS share price has zoomed 8% and is presently trading at Rs 13.8.
Meanwhile, the BSE HEALTHCARE index is at 38,114.1 (down 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.0%) and GLAND PHARMA (up 1.9%).
Divis Laboratories (down 3.1%) and CAPLIN POINT (down 2.7%) are among the top losers today.
Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 7.6 to Rs 13.8, registering a gain of Rs 6.3 (up 83.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,703.5 to 38,114.1, registering a gain of 48.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 107.6%), Cadila Healthcare (up 104.1%) and Lupin (up 99.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,897.2 (down 0.1%).
The top losers among the BSE Sensex today are Titan (down 4.0%) and MUNDRA PORT & SEZ (down 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.
In the meantime, NSE Nifty is at 24,272.7 (down 0.2%). Titan and Divis Laboratories are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,479.1 to 79,897.2, registering a gain of 14,418.2 points (up 22.0%).
SYNCOM FORMULATIONS net profit fell 12.6% YoY to Rs 74 million for the quarter ended March 2024, compared to a profit of Rs 85 million a year ago. Net sales rose 22.3% to Rs 746 million during the period as against Rs 610 million in January-March 2023.
For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.
The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 51.3.
Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 8%; BSE HEALTHCARE Index Down 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!